Sign in
CompletedNo phase

The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study

Key facts

Who runs it
Edwards Lifesciences
Where
Aurora, Charlotte, Charlottesville, Detroit, Evanston, Los Angeles, Morristown, and Plano, United StatesSee the 8 sitesAlso in 6 other countries, 9 sites
Trial code
Status
Completed
People taking part
124 people enrolled
Started
27 Jun 2017
Ended
27 May 2025
Type of study
Interventional
Treatments tested
  • Mitral Valve Repair
Record updated
5 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Signed and dated IRB/ethics committee approved study consent form prior to study related procedures
  • Eighteen (18) years of age or older
  • New York Heart Association (NYHA) Functional Class II-IVa heart failure despite optimal medical therapy
  • Candidacy for surgical mitral valve repair or replacement determined by Heart Team evaluation
  • Clinically significant mitral regurgitation (moderate-to-severe or severe mitral regurgitation) confirmed by transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE)
  • The primary regurgitant jet is non-commissural. If a secondary jet exists, it must be considered clinically insignificant
  • Mitral valve area (MVA) ≥ 4.0 cm² as measured by planimetry. If MVA by planimetry is not measurable, pressure half-time measurement is acceptable

Who cannot take part

  • Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
  • Patient is currently participating or has participated in another investigational drug or device clinical study where the primary study endpoint was not reached at time of enrollment
  • Physical evidence of right sided congestive heart failure and echocardiographic evidence of severe right ventricular dysfunction
  • Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
  • Leaflet anatomy which may preclude PASCAL device implantation, proper device positioning on the leaflets, or sufficient reduction in mitral regurgitation
  • Mitral valve area (MVA) < 4.0 cm² as measured by planimetry (If MVA by planimetry is not measurable, PHT measurement is acceptable)
  • Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
  • Patient is under guardianship

Where in United States

Also in 6 other countries, 9 sites

  • University of Colorado DenverAurora, United States
  • Carolinas Medical CenterCharlotte, United States
  • University of Virginia Health SystemCharlottesville, United States
  • Henry Ford HospitalDetroit, United States
  • NorthShore University HealthSystemEvanston, United States
  • Cedars-Sinai Medical CenterLos Angeles, United States
  • Morristown Medical CenterMorristown, United States
  • The Heart Hospital Baylor PlanoPlano, United States

About the trial

What the trial wants to find out

The purpose of this study is to assess the safety, performance and clinical outcomes of the Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System.

The group in the trial

  • Edwards PASCAL Transcatheter Mitral Valve Repair SystemTreatment being tested

    Treatment: Mitral Valve Repair

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
5 February 2026